The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor by unknown
Brief DeBnitive  Report 
The Type H "Receptor" As a Decoy Target for 
Interleukin  1 in Polymorphonuclear Leukocytes: 
Characterization  of Induction  by Dexamethasone 
and Ligand Binding Properties  of the Released 
Decoy Receptor 
By Fabio  Re,  Marta  Muzio,  Marco De l%ssi,  Nadia Polentarutti, 
Judith  G.  Giri;  Alberto  Mantovani,  and Francesco  Colotta 
From the lstituto di Ricerche Farmacologiche "Mario Negri;' Centro Daniela e Catullo 
Borgomainerig 20157 Milang Italy; and the *Detmnraent of Immunology, Irasunex Research 
and Development Corporation, Seattle, Washington 98101 
Summary 
Whereas the signaling function of the interleukin 1 (IL-1) receptor type I (IL-1R I) has been 
well documented, the type II "receptor" has been suggested to act as a decoy target for this 
cytokine. Since IL-1 may represent a key target of the immunomodulatory and antiinflammatory 
properties  of glucocorticoids (GC),  the aim of this study was to  investigate  the effects of 
dexamethasone  (Dex) on IL-1R expression in human polymorphonuclear leukocytes (PMN), 
which express predominantly the type II molecule (IL-1R II). We found that Dex augments 
the levels of steady state transcripts encoding the IL-1R I and, most prominently, those of IL-1R 
II. Dex induced both transcripts  via transcription-dependent mechanisms and by prolongation 
of the mRNAs half-lives. Inhibition of protein synthesis superinduced basal and Dex-augmented 
IL-1R II mKNA, whereas it completely inhibited the induction by Dex of IL-1R I transcripts. 
Induction of IL-1R II mKNA by Dex was associated with augmented membrane expression 
and release of the type II IL-1 binding molecule. This effect was mediated by the GC receptor. 
Other steroids (17~5-estradiol, progesterone, and testostmone) were ineffective. The concentrations 
of IL-lot and IL-1 receptor antagonist required to displace the binding of IL-1/5 to the soluble 
form of the decoy molecule induced by Dex from PMN were, respectively, 100 and 2 times 
higher compared with IL-1/3. The induction by Dex of the type II receptor, a decoy molecule 
for IL-1, may contribute to the immunosuppressive  and antiinflammatory activities of Dex. 
G 
lucocorticoids (GC) are potent modulators of the im- 
mune and inflammatory responses in humans and ex- 
perimental models.  IL-1,  a key mediator of inflammatory 
reactions (1), represents an important target of GC-mediated 
immunosuppressive  activities. GC suppress IL-1 production 
by monocyte-macrophages,  both in vitro and in vivo (2-9). 
In apparent contrast with the inhibitory activities of GC on 
IL-1, GC were found to increase the expression of 1L-1IL on 
different cell types, including human PBMC (10, 11), PMN 
(11, 12), and the B ceU llne Raji (13). 
Two IL-1Ks have been identified and cloned. The IL-1IL 
I is an 80-kD transmembrane protein expressed  predominantly 
or exclusively in T lymphocytes, fibroblasts, and endothdial 
cells, whereas the most represented receptor on mydomono- 
cytic ceils and B lymphocytes is the 68-kD (type II) IL-1R 
II (14, 15). Although the IL-1R I has a demonstrated trans- 
membrane signaling function (16-22),  the role of IL-1R II, 
which has a short (29-aa) cytoplasmic tail, is still a matter 
of investigation.  Efforts aimed at defining a signaling func- 
tion for IL-1R II using blocking mAbs have failed (22). 
Moreover, studies on regulation of PMN survival by IL-1 
and IL-4 have suggested  that the IL-1R II acts as a decoy 
target for IL-1 (23). 
Given the importance of GC as antiinflammatory and im- 
munosuppressive agents, this study was designed to conduct 
an in depth analysis of the regulation by GC of IL-1 receptors 
in human PMN. 
Materials and Methods 
Cells.  Human PMN were separated from the peripheral  blood 
of human healthy donors by Percoll  gradient centrifugation (23). 
Briefly, whole blood was fractionated  by Ficoll  gradient centrifu- 
gation (Seromed-Biochem  KG, Berlin, Germany), and PMN, col- 
lected from the pellet, layered  on top of 62% Percoll (Pharmacia, 
Uppsala, Sweden).  PMN (~98% pure as assessed  by morphology) 
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(Hyclone Laboratories, Logan, UT). 
Reagents.  Dexamethasone  (Dez), cortexolone (17-hydroxyl-ll- 
deoxycorticosterone),  progesterone, 17/3-estradiol,  and testosterone 
were from Sigma Chemical Co. (St. Louis, MO). RU 486 was a 
kind gift of  Dr. D. Di Lorenzo, Brescia, Italy. IL-lo~  and IL-1B  were 
from Immunex Research and Development  Corp. IL-1  receptor an- 
tagonist (IDlra) was from Cetus Corp. (Berkeley, CA). 
11,1 Binding Assay.  After  treatment  with 10 -7 M De~ for 
12-14 h at 37~  1-2  x  10  ~  PMN were incubated with decreasing 
concentrations of 12sI-IL-1/3 (180/zCi//Lg; NEN, Bad Homburg, 
Germany) in the presence or absence of a 200-fold molar excess 
of cold cytokine in 0.1 ml binding buffer (PBS-0.1% BSA-0.02% 
sodium azide; Sigma Chemical Co.) at room temperature for 1 h. 
To separate  bound from free radiohbded ID1, cells  were centrifuged 
over a cushion of silicon oil Scatchard analysis  was performed by 
the LIGAND program (24). 
Northern  Blot  Analysis.  KNA isohtion and analysis  were as de- 
scribed (23). Probes were a EcoKI-HindlII 477-bp fragment and 
a EcoKI-SalI 750-bp fragment from Iblg I and ID1R II cDNAs, 
respectively.  Membranes  were washed  twice with 2x SSC/1% SDS 
(Merck & Co., Inc., Rahway,  NJ) at 60~  and exposed  for 24-36 h 
for IDIK I or 4-6 h for ID1K II expression  at -80~  KNA transfer 
to membranes was checked by UV irradiation. 
A~inity Cross-linking.  Cross-linking  experiments  were described 
in detail (23). Briefly, for surface affinity cross-linking, 30  x  106 
PMN  treated  with  10 -7  M  Dex for  14  h  were incubated in 
binding buffer with 1 nM lzsI-IL-13. After addition of 1 mM di- 
succinimidyl  suberate (DSS; Pierce Chemical Co., Rockford, IL), 
the cell pellet was lysed  in 100/~1 lysis  buffer (0.5% Triton X-100, 
25 mM Hepes, I mM PMSF, 100/~g/ml aprotinin and leupeptin; 
Sigma Chemic.a1 Co.). The debris-free superuatant was analyzed 
by 8% SDS-PAGE under reducing conditions and dried gels were 
exposed to autoradiography for 1-3 d. For soluble covalent cross- 
linking, 30  x  106 PMN were cultivated with 10 -7 M Dex for 
14 h in RPMI 1640 without serum at 37~  Medium was recov- 
ered and concentrated 10 times by membrane filtration (cut-off 
10,000; Amicon, Beverly, MA). 200/zl were added with 1 nM 
l~sI-IL-1/5, with or without a 2-2000-molar excess of cold com- 
petitors (IL-lo~, ID13, and IL-lra), and incubated at 4~  for I h. 
After addition of 1 mM DSS at 4~  for 30 rain,  samples were 
analyzed  by gel electrophoresis as above. Densitometric analysis  of 
autoradiographic signals  has been performed with a scanning den- 
sitometer (GS 300; Hoefer Scientific  Instruments, San Francisco, 
CA), calculating the area under the curve. 
Figure  1.  Induction  of IDIR I and IblR II transcripts  in Dex-treated 
PMN. Cells were incubated  with 10 -7 M Dex for 1, 5, and 18 h. Total 
ILNA  was extracted  and analyzed  by Northern blotting. The same  mem- 
brane was hybridized,  first with the IL-1R I probe, and then with the 
IL-1R II probe. The lower part of the figure shows the ethidium  bro- 
mide-stained  membrane.  The membrane  was exposed  to autoradiography 
for 25 and 5 h for type I and type II transcripts, respectively. 
Different Mechanisms Are Involved in Induction of Type I and 
Type II IL-1R Expression.  Next we examined the mecha- 
nisms involved in the induction of IL-LR I and IL-1R II tran- 
scripts by Dex. Actinomycin  D (ActD) completely abolished 
the augmented expression  of both type I and type II tran- 
scripts induced by Dex (Fig. 2, representative of  four donors), 
indicating that gene transcription is involved in this phenom- 
enon. We encountered considerable difficulties in performing 
run-off analysis in human circulating PMN. In one experi- 
ment with the lymphoblastoid B cell line Raji, Dex induced 
augmented levels of type II IL-1R transcription (data not 
shown). When transcript stability was examined, the half- 
lives of type I and type II R  transcripts in untreated cells 
Results and Discussion 
Dex  Stimulates Predominantly IL-IR  II  mRNA  Expres- 
sion.  Untreated PMN expressed abundant levels of the type 
II mRNA and these were considerably increased (4-10-fold, 
six donors) by Dex, with peak levels at 4-5 h (Fig. 1). Visual- 
ized by Northern analysis, PMN have barely detectable or 
undetectable levels of type I IL-1R mKNA (11, 23). Dex aug- 
mented also IL-1K I transcripts  (three- to sixfold, six donors), 
but constitutive and inducible transcripts coding for IL-1R 
I were evident only after long times of exposure (the mem- 
branes shown in Hg. 1 were exposed to autoradiography for 
25 h for the type I R and 5 h for type lI K transcripts). Thus, 
the predominant IL-1R transcripts induced by Dex in PMN 
are those coding for the IL-1R II. 
Figure  2.  Effects  of  metabolic  inhibitors  on Dex-induced  expression  of 
IIvK transcripts. PMN from two different  donors, representative  of four, 
were incubated  with Dex (10-  7 M), with or without ActD (1/~g/ml) 
or CH (10/~g/ml), for 4 h and then analyzed  for IblR I and IL-1R II 
transcripts. Each  membrane  (bottom)  was hybridized  with both probes and 
exposed to autoradiography  as detailed in Hg. 1. 
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Dex-treated PMN 
Exp.  De):  Kd  Receptors/cell 
(10 -10 M) 
1  -  5.98  +  0.7  111  +  17 
+  6.72  •  0.8  381  _+  61 
2  -  8.1  _+  1.6  220  +  55 
+  7.9  _+  1.5  854  _+  154 
3  -  7.5  +  1.1  124  •  31 
+  8.4  _+  1.3  794  •  190 
PMN were purified  from three donors  and  incubated  with or without 
Dex (10-7 M) for 14 h.  Cells were then incubated  with various con- 
centrations  of radiolabded IL-1B (from 1.2 to 0.05 nM). Specific bind- 
ing was obtained  after  subtraction  of counts in the presence of 200 M 
excess of unlabeled  IL-1/~. 
Figure  3.  Half-life of IL-1R transcripts  in PMN untreated  or treated 
with Dex. PMN were cultivated with or without Dex (10- 7 M) for 4 h. 
Then ActD was added (1/~g/ml) to block gene transcription  and cells 
examined for IL-1R transcripts  after various time points.  The same mem- 
brane (bottom)  was hybridized with both probes and exposed to autoradi- 
ography  as detailed  in Fig.  1. 
were ~2 and 3 h, respectively (Fig. 3, representative of three 
donors). Dex increased IL-1K transcript stability, prolonging 
the half-lives of type I and type II R to --15 and 7 h, respec- 
tively. 
Thus, Dex affects the expression of IL-1K I and IL-1K 
II at transcriptional  and posttranscriptional  levels. However, 
different mechanisms seem to underlie the Dex-mediated in- 
duction of these transcripts  since inhibition of protein syn- 
thesis by cycloheximide  (CH) superinduced  the Dex-aug- 
mented expression of type II IL-1K mKNA but completely 
inhibited the induction of type I IL-1K transcripts  (Fig. 2, 
representative  of four donors). 
Dex.induced  Surface  Expression  and Release of  lL-1R II.  As 
expected (11, 12), Dex caused a three- to sixfold increase in 
specific binding of IL-I~ to PMN, with unchanged Ka values 
(Table 1). Surface affinity cross-linking demonstrated an IL-1 
receptor with a molecular mass consistent with the type II 
IL-1 binding protein (68 kD) (Fig. 4 A iUustrates a represen- 
tative donor out of three tested). 
Augmented surface expression of the type II IL-1K was 
associated  with release  of a soluble version of this IL-1 binding 
protein. Cross-linking revealed that the supernatants of Dex- 
treated PMN contained an IL-l-binding protein of apparent 
Figure  4.  Surface expression and release of IL-1K II from PMN treated 
with Dex, GC receptor antagonists, and other steroids. (A) Surface affinity 
cross-linking  of radiolabeled IL-I~ to Dex (10-7 M, 14 h)-treated  PMN. 
The first lane on the left shows molecular  weight markers.  (B) Affinity 
cross-linking  of radiolabeled I1.-1~ to conditioned supernatants  of PMN 
treated with Dex at various concentrations.  Cells were incubated for 14 h 
with Dex from 10 -6 to 10 -s M. Conditioned media were then concen- 
trated and incubated with radiolabded  IL-I~. After treatment with DSS, 
cross-linked products  were analyzed by SDS-PAGE under reducing  con- 
ditions.  (C)  Affinity cross-linking  radiolabeled  I1.~1~ to  conditioned 
media of PMN treated  for 14 h with the following steroid and steroid- 
receptor  antagonist:  Dex  (10 .7  M),  RU 486  (10-6  M),  cortexolone 
(cortex,  10-s M), progesterone  (10 .7 M), testosterone (10-~ M), 17B-es- 
tradiol  (10 .7 M). 
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IL-lra of at~nity cross-linking of" radiolabded IL-I~ to Dex-treated PMN- 
conditioned  media.  Cells were incubated for 14 h with Dex (10-7 M). 
The conditioned media were next concentrated and incubated with radio- 
labeled II.,1B and the different competitors  at increasing molar excess (as 
indicated). After treatment  with DSS, products  were analyzed by SDS- 
PAGE under reducing conditions.  The densitometric  analysis of the an- 
toradiographic  film is illustrated below. 
molecular weight of "-'45 kD (Fig. 4 B). This finding was 
confirmed in 10 different donors. Soluble IL-1 binding pro- 
teins of comparable size have been described in the superna- 
tants from human mononudear cells and from the B cell line 
Raji (25-27). Using mAbs, we recently established that the 
45-kD IL-1 binding molecule released from PMN is a ver- 
sion of the type II IL-1tL (23). Moreover, in preliminary ex- 
periments, Dex-induced release of the type II R  as assessed 
using  a  specific ELISA  assay (six  donors,  increase  from 
2.3-3.75-fold). A  toxic effect of 10-6-10 -s M Dex can be 
ruled out, since neither LDH release nor cell viability (trypan 
blue dye exclusion) were affected by the treatment (data not 
shown). 
The release of a soluble form of the type II IL-1 binding 
protein by Dex was mediated by the glucocorticoid  receptor, 
as two different competitive analogs (cortexolone and RU 
486) prevented the Dex-mediated release of this IL-1 binding 
protein from PMN (Fig. 4 C). RU 486 inhibited the induc- 
tion of IL-1R II transcripts by Dex (not  shown).  Other 
steroids, including progesterone, 17-B-estradiol,  and testos- 
terone, were ineffective (Fig.  4 C). 
Relative A~nities of the Soluble T~qJe II Molecule to IL-lce, 
IL-1{3, and IL-1 Receptor  Antagonist (IL-lra).  Since the mem- 
brane form of the decoy receptor binds IL-lce, IL-1B,  and 
IL-lra with different affinities (28-30), the binding proper- 
ties of the corresponding soluble version were examined by 
competing the affinity cross-linking of radiolabeled IL-1/3 to 
the soluble IL-1R II with various concentrations of unlabeled 
IL-lo~, IL-113, and IL-lra. In a preliminary experiment, the 
competitive system used here was validated using recombinant 
soluble IL-1R I (data not shown). Ahhough formal binding 
analysis requires the purified sohble protein, the densitometric 
analysis of cross-linked products was used to demonstrate that 
the concentrations of IL-lra and IL-lc~ capable of inhibiting 
binding of radiolabded IL-113  by 50% were 2 and 100 times 
higher, respectively,  compared with IL-113 (Fig.  5). 
Concluding Remarks.  GC have a wide range of effects on 
various components of immune and inflammatory  responses. 
The precise mechanisms underlying the immunosuppressive 
and anti-inflammatory activities of GC have not been com- 
pletdy defined. GC have been shown to inhibit the synthesis 
of a series of cytokines involved in the regulation of inflam- 
matory reactions, including IL-1 (2-9). The finding that GC, 
a major class of immunosuppressive and antiinflammatory 
agents, induce expression and rdease of the type II IL-1 binding 
molecule is consistent with the hypothesis that this mole- 
cule, perhaps inappropriately called a receptor,  may indeed 
serve as a decoy target for IL-1  (23). 
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